# PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

> **NCT06762405** · PHASE3 · RECRUITING · sponsor: **Centre Hospitalier Universitaire Dijon** · enrollment: 68 (estimated)

## Conditions studied

- Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)

## Interventions

- **RADIATION:** radiotherapy
- **DRUG:** Dostarlimab
- **BIOLOGICAL:** Biological study on circulating tumor DNA (optional for the patient)

## Key facts

- **NCT ID:** NCT06762405
- **Lead sponsor:** Centre Hospitalier Universitaire Dijon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-06
- **Primary completion:** 2030-09
- **Final completion:** 2030-09
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06762405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06762405, "PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06762405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*